Barclays
NVAX icon

Barclays’s Novavax NVAX Stock Holding History

Barclays’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$478K – 5174
2024
Q1 		$478K Sell
100,000
-290,000
-74% -$1.34M ﹤0.01% 3624
2023
Q4 		$1.87M Buy
+390,000
New +$2.39M ﹤0.01% 2968
2023
Q2 		– Sell
-7,400
Closed -$51.3K – 4929
2023
Q1 		$51.3K Sell
7,400
-2,100
-22% -$19.3K ﹤0.01% 4435
2022
Q4 		$97.7K Buy
+9,500
New +$168K ﹤0.01% 4236
2022
Q3 		– Sell
-174,900
Closed -$8.99M – 5035
2022
Q2 		$8.99M Buy
+174,900
New +$9.06M 0.01% 1056
2019
Q2 		– Sell
-91,560
Closed -$1.01M – 7143
2019
Q1 		$1.01M Buy
91,560
+48,935
+115% +$1.54M ﹤0.01% 3390
2018
Q4 		$1.57M Buy
+42,625
New +$1.65M ﹤0.01% 2654
2017
Q1 		– Sell
-9,500
Closed -$239K – 6911
2016
Q4 		$239K Sell
9,500
-11,385
-55% -$332K ﹤0.01% 4073
2016
Q3 		$869K Buy
20,885
+11,385
+120% +$1.47M ﹤0.01% 2754
2016
Q2 		$1.38M Buy
+9,500
New +$1.09M ﹤0.01% 2332
2015
Q4 		– Sell
-795
Closed -$111K – 6396
2015
Q3 		$111K Buy
+795
New +$178K ﹤0.01% 4560

Other funds holding NVAX

SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's NVAX Position: Q1 2026 in Review

Barclays increased its Novavax (NVAX) stake by 8.1% in Q1 2026, buying an estimated $805K and bringing the position to 1,191,079 shares worth $9.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1465.

Barclays first reported a position in NVAX in Q2 2013 and has held it in 52 quarters since. The position peaked at $44.3M in Q2 2021. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Barclays held 1,191,079 shares of Novavax worth $9.7M as of Q1 2026.
  • Barclays bought 88,779 Novavax shares in Q1 2026, an estimated $805K.
  • Novavax made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1465 holding.
  • Barclays first reported a position in Novavax in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Novavax position peaked at $44.3M in Q2 2021.
  • 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.